Publication | Closed Access

Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni

Critical Care MedicineSevere SepsisClinical TherapeuticAcute CarePatient SafetySepsisSepsis PhenotypingPharmacotherapy90-Day SurvivalMedicineDrotrecogin AlfaClinical Microbiology